Literature DB >> 19401521

The impact of consenter characteristics and experience on patient interest in clinical research.

Drew W Rasco1, Yang Xie, Jingsheng Yan, Jennifer R Sayne, Celette Sugg Skinner, Jonathan E Dowell, David E Gerber.   

Abstract

BACKGROUND: To explain the historically low rates of participation in cancer clinical trials, several factors have been studied. These include subject characteristics and attitudes, clinical trial availability and eligibility criteria, and physician attitudes and communication skills. However, the impact of nonphysician research personnel, who often consent patients for studies, is unclear. We therefore evaluated the association between consenter characteristics and subject interest in clinical research.
METHODS: We performed a retrospective review of subjects enrolled in a university-based cancer center tissue repository. During enrollment, subjects were asked if they were willing to be contacted in the future to (a) provide medical follow-up information and (b) participate in other clinical research. We analyzed the association between responses to these questions and consenter characteristics using univariate analysis and multivariate logistic regression.
RESULTS: In total, 181 consenters enrolled 922 subjects. The majority of subjects agreed to be contacted for follow-up (84.9%) and future research (83.1%). Subject willingness to be contacted for future research was associated with greater consenter experience in univariate and multivariate analyses. In multivariate analysis, subject willingness to be contacted for future research was associated with discordance between subject and consenter gender, but not with subject gender, race, or income, or consenter gender or race.
CONCLUSIONS: Consenter experience and subject-consenter gender discordance were associated with greater subject interest in participating in future research. The role of consenters in clinical research merits future study and should be considered in efforts to increase cancer clinical trial accrual.

Entities:  

Mesh:

Year:  2009        PMID: 19401521     DOI: 10.1634/theoncologist.2008-0268

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  12 in total

1.  Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  J Natl Cancer Inst       Date:  2015-02-09       Impact factor: 13.506

2.  Conceptual Model for Accrual to Cancer Clinical Trials.

Authors:  Simon J Craddock Lee; Caitlin C Murphy; Ann M Geiger; David E Gerber; John V Cox; Rasmi Nair; Celette Sugg Skinner
Journal:  J Clin Oncol       Date:  2019-06-05       Impact factor: 44.544

3.  Impact of prior cancer on eligibility for lung cancer clinical trials.

Authors:  David E Gerber; Andrew L Laccetti; Lei Xuan; Ethan A Halm; Sandi L Pruitt
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

4.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

5.  Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials.

Authors:  Sandra Garcia; Jessica M Saltarski; Jingsheng Yan; Xian-Jin Xie; David E Gerber
Journal:  Clin Lung Cancer       Date:  2017-05-08       Impact factor: 4.785

6.  Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.

Authors:  David E Gerber; Ashley M Lakoduk; Laurin L Priddy; Jingsheng Yan; Xian-Jin Xie
Journal:  Oncologist       Date:  2015-05-27

7.  Consent timing and experience: modifiable factors that may influence interest in clinical research.

Authors:  David E Gerber; Drew W Rasco; Celette Sugg Skinner; Jonathan E Dowell; Jingsheng Yan; Jennifer R Sayne; Yang Xie
Journal:  J Oncol Pract       Date:  2011-12-06       Impact factor: 3.840

8.  Cancer patient perceptions about biobanking and preferred timing of consent.

Authors:  Kathryn L Braun; Joann U Tsark; Amy Powers; Kristen Croom; Robert Kim; Francine C Gachupin; Paul Morris
Journal:  Biopreserv Biobank       Date:  2014-04       Impact factor: 2.300

9.  Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial.

Authors:  David E Gerber; Heidi A Hamann; Claudia Chavez; Olivia Dorsey; Noel O Santini; Travis Browning; Cristhiaan D Ochoa; Joyce Adesina; Vijaya Subbu Natchimuthu; Eric Steen; Hong Zhu; Simon J Craddock Lee
Journal:  Clin Lung Cancer       Date:  2020-02-26       Impact factor: 4.785

10.  Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study.

Authors:  Norma F Kanarek; Marty S Kanarek; Dare Olatoye; Michael A Carducci
Journal:  Trials       Date:  2012-12-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.